Although oncogenic mutations of BRAF are only seen in a small proportion of colon cancers, they pose a great challenge in the treatment of the disease, in that colon cancers with mutations in BRAF, similar to those with mutations in KRAS, are resistant to conventional chemotherapeutic drugs and agents targeting EGFR [4–6, 38]. Here, BRAF is linked to malignant colon neoplasm.